Company history

Nakanishi began in 1930, when Nakanishi Haruo opened a dental-instrument workshop in Kanuma, a provincial town in Tochigi Prefecture, well away from Tokyo or Osaka. Pre-war Japan imported most of its dental equipment, so there was room for a domestic maker; what Nakanishi built through the shortages of the war and the recovery that followed was a narrow reputation as a specialist supplier to dental clinics. The business was incorporated in 1951, and through the high-growth decades it accumulated, in-house, the precision machining that rotary dental instruments demand.

The decision that defined the company came in 1971, four decades in, when Nakanishi began building turbines that spun at 400,000 revolutions per minute. In dentistry the logic is direct: the faster the tip turns, the faster it cuts and the less the patient endures. Rather than supply the full range of instruments a clinic needs, Nakanishi concentrated its engineering on the rotating parts alone — a choice that also happened to produce excellent economics, since a cartridge at the tip of a handpiece wears out in about a year and must be replaced.

In June 1982 the same mechanism was pointed at a second, quite different customer. Dental handpieces and the industrial spindles used to cut moulds and drill circuit boards are different products serving different trades, but they are the same engineering problem — holding a tool true at hundreds of thousands of rpm. With the domestic dental market flattening, Nakanishi opened an industrial line in cutting and polishing equipment, and found little competition in small-diameter high-speed spindles.

In July 1984 Nakanishi set up NSK-AMERICA CORP. near Chicago — its first overseas subsidiary, and the template for everything that followed. Rotary dental equipment is not a product that can simply be shipped: clinical practice, regulation and distribution differ country by country, and an instrument is only usable if someone nearby can service it. Rather than hand that to distributors, Nakanishi chose to own the front line itself.

The margins came from vertical control at home. Nakanishi developed every product itself — mechanical design, electronics, microcontroller firmware — and made 80–85% of its parts in-house, building even the special-purpose machine tools required to do so. Because its products were small, high-value items that could travel by parcel courier, it could serve the world without a heavy sales infrastructure. President Nakanishi Eiichi later credited that combination — expensive-per-gram products, cheap logistics, nothing bought that could be made — with an ordinary profit margin above 30%.

Two further moves fixed the company’s standing. In 1993 it was first in the world to build a clean head system, which stops blood and saliva being sucked back into a turbine as it stops — a route for cross-infection — and won the top technical prize at the Paris dental exhibition for it. Then, in January 1996, the maker renamed itself Nakanishi Inc. and, that July, absorbed its own sales agent, putting manufacturing and selling inside a single company. By 2000 it held roughly 15% of the world dental market, second only to Germany’s KaVo, with 60–80% shares in South-East Asia and exports at about 70% of sales.

In May 2000 Nakanishi Eiichi, the founder’s eldest son, became president; two months later the company registered its shares over the counter. Succession and public listing arrived in the same year. It was a small company to be going public — sales of $67.8M (¥7bn) in the year to February 2000 — but the profitability behind those sales, above 30% at the ordinary line, was what the market was buying. The listing venue then moved with Japan’s own consolidation: to JASDAQ in 2004, to the Osaka exchange’s JASDAQ in 2010, and to the Tokyo Stock Exchange’s JASDAQ in 2013.

What the listing funded was the replication of the 1984 American experiment everywhere else. NSK EUROPE GmbH opened in Frankfurt in 2003, a European holding company in Luxembourg in 2004, and in 2005 Nakanishi bought its French distributor outright and turned it into NSK FRANCE S.A.S. — competing directly, with its own staff, on the home ground of the market leader. Shanghai followed in 2005, then Australia and New Zealand, the United Kingdom, Spain, a South-East Asian hub in Singapore in 2012, Brazil in 2013, Korea in 2014 and the UAE in 2017. Overseas sales climbed toward 90% of the total.

In July 2013 came the first acquisition of substance: DENTAL X S.p.A, an Italian maker of sterilizers. Handpieces are reused, and reuse means sterilization; owning both let Nakanishi sell the process rather than the tool. Group revenue roughly doubled from about $213.8M (¥20bn) in 2009 to $330.6M (¥37bn) in 2018, with operating margins held near 30% — a genuinely narrow business, sold in more than a hundred countries, earning like a much broader one.

From 2020 the engine changed. Having deepened one narrow technology as far as it would go, Nakanishi began buying adjacent businesses instead of building them: a roughly 33% stake in DCI International, an Oregon maker of dental treatment units, in October 2020; Germany’s Alfred Jäger, in high-frequency spindles, in December 2022; the remaining DCI shares and China’s Guilin REFINE in 2023. A DCI segment joined the historic dental and industrial ones, and in March 2026 the company announced the acquisition of Acra Cut and Intech in the United States, extending the same logic into surgical instruments.

The arithmetic was immediate. Consolidated revenue went from $309M (¥33bn) in the year to December 2020 to $508.3M (¥77bn) in 2024 — 2.33 times in four years — with operating profit rising from $79.6M (¥9bn) to $95.7M (¥15bn) and headcount up some 86%, from 1,184 to 2,204. No amount of in-house development compounds at that rate.

The profitability did not travel as fast as the revenue. In the year to December 2025, sales reached $541.9M (¥81bn) and operating profit $93.6M (¥14bn), but an impairment on the DCI business inside $92.2M (¥14bn) of extraordinary losses pushed the group to a net loss of about $16M (¥2bn). The mid-term plan NV2030, announced in August 2025, keeps M&A at the centre of strategy and aims to raise Nakanishi’s standing in dental and surgical worldwide. Ninety-five years after Kanuma, the open question is whether a company that machined its own 30% margins can impose them on businesses it bought.